Neuroinflammation in Parkinson's disease.
Identifieur interne : 000E23 ( Ncbi/Curation ); précédent : 000E22; suivant : 000E24Neuroinflammation in Parkinson's disease.
Auteurs : Etienne C. Hirsch [France] ; Sheela Vyas ; Stéphane HunotSource :
- Parkinsonism & related disorders [ 1873-5126 ] ; 2012.
English descriptors
- KwdEn :
- Animals, Anti-Inflammatory Agents, Non-Steroidal (therapeutic use), Humans, Inflammation (drug therapy), Inflammation (metabolism), Inflammation (pathology), Nerve Degeneration (drug therapy), Nerve Degeneration (metabolism), Nerve Degeneration (pathology), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (pathology).
- MESH :
- chemical , therapeutic use : Anti-Inflammatory Agents, Non-Steroidal.
- drug therapy : Inflammation, Nerve Degeneration, Parkinson Disease.
- metabolism : Inflammation, Nerve Degeneration, Parkinson Disease.
- pathology : Inflammation, Nerve Degeneration, Parkinson Disease.
- Animals, Humans.
Abstract
Both epidemiological and genetic studies support a role of neuroinflammation in the pathophysiology of Parkinson's disease (PD). Furthermore, post mortem studies confirm the involvement of innate as well as adaptive immunity in the affected brain regions in patients with PD. Indeed, activated microglial cells and T lymphocytes have been detected in the substantia nigra of patients concomitantly with an increased expression of pro-inflammatory mediators. Preclinical investigations conducted in various animal models of PD indicate that inflammatory processes are instrumental in neuronal cell death even though they are unlikely to be a primary cause for neuronal loss. Neuroinflammatory processes in PD are rather involved in self-perpetuating deleterious events that lead to protracted neuronal degeneration. In line with this, recent data indicate that glucocorticoid receptors are important in curtailing microglial reactivity, and deregulation in their activity in PD could lead to sustained inflammation-mediated degeneration. Altogether, neuroinflammatory processes might represent a target for neuroprotection in PD.
DOI: 10.1016/S1353-8020(11)70065-7
PubMed: 22166438
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000913
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000873
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000873
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000E23
Links to Exploration step
pubmed:22166438Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroinflammation in Parkinson's disease.</title>
<author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C" last="Hirsch">Etienne C. Hirsch</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, UMR_S975, CRicm, Experimental Therapeutics of neurodegeneration, F-75013, Paris, France. etienne.hirsch@upmc.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR_S975, CRicm, Experimental Therapeutics of neurodegeneration, F-75013, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vyas, Sheela" sort="Vyas, Sheela" uniqKey="Vyas S" first="Sheela" last="Vyas">Sheela Vyas</name>
</author>
<author><name sortKey="Hunot, Stephane" sort="Hunot, Stephane" uniqKey="Hunot S" first="Stéphane" last="Hunot">Stéphane Hunot</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22166438</idno>
<idno type="pmid">22166438</idno>
<idno type="doi">10.1016/S1353-8020(11)70065-7</idno>
<idno type="wicri:Area/PubMed/Corpus">000913</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000913</idno>
<idno type="wicri:Area/PubMed/Curation">000873</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000873</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000873</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000873</idno>
<idno type="wicri:Area/Ncbi/Merge">000E23</idno>
<idno type="wicri:Area/Ncbi/Curation">000E23</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroinflammation in Parkinson's disease.</title>
<author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C" last="Hirsch">Etienne C. Hirsch</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, UMR_S975, CRicm, Experimental Therapeutics of neurodegeneration, F-75013, Paris, France. etienne.hirsch@upmc.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR_S975, CRicm, Experimental Therapeutics of neurodegeneration, F-75013, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vyas, Sheela" sort="Vyas, Sheela" uniqKey="Vyas S" first="Sheela" last="Vyas">Sheela Vyas</name>
</author>
<author><name sortKey="Hunot, Stephane" sort="Hunot, Stephane" uniqKey="Hunot S" first="Stéphane" last="Hunot">Stéphane Hunot</name>
</author>
</analytic>
<series><title level="j">Parkinsonism & related disorders</title>
<idno type="eISSN">1873-5126</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term>
<term>Humans</term>
<term>Inflammation (drug therapy)</term>
<term>Inflammation (metabolism)</term>
<term>Inflammation (pathology)</term>
<term>Nerve Degeneration (drug therapy)</term>
<term>Nerve Degeneration (metabolism)</term>
<term>Nerve Degeneration (pathology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (pathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Inflammation</term>
<term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Inflammation</term>
<term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Inflammation</term>
<term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Both epidemiological and genetic studies support a role of neuroinflammation in the pathophysiology of Parkinson's disease (PD). Furthermore, post mortem studies confirm the involvement of innate as well as adaptive immunity in the affected brain regions in patients with PD. Indeed, activated microglial cells and T lymphocytes have been detected in the substantia nigra of patients concomitantly with an increased expression of pro-inflammatory mediators. Preclinical investigations conducted in various animal models of PD indicate that inflammatory processes are instrumental in neuronal cell death even though they are unlikely to be a primary cause for neuronal loss. Neuroinflammatory processes in PD are rather involved in self-perpetuating deleterious events that lead to protracted neuronal degeneration. In line with this, recent data indicate that glucocorticoid receptors are important in curtailing microglial reactivity, and deregulation in their activity in PD could lead to sustained inflammation-mediated degeneration. Altogether, neuroinflammatory processes might represent a target for neuroprotection in PD.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000E23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:22166438 |texte= Neuroinflammation in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:22166438" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |